5 OPERATING EXPENDITURES (CONTINUED) For the year ended 30 June 2025 $ For the year ended 30 June 2024 $ Research and Development Employee Expenditure - Staff wages and superannuation 1,192,047 1,147,854 - Other employment expenses 120,012 60,389 1,312,059 1,208,243 R&D Expenditure - External R&D 408,648 385,874 - Laboratory operations 1,282,858 865,538 1,691,506 1,251,410 Depreciation and Amortisation - Depreciation of building improvements 9,381 9,381 - Depreciation of right-of-use assets – AASB 16 Leases 96,788 137,877 - Depreciation of plant and equipment 144,819 92,680 250,987 239,937 Per consolidated Statement of Comprehensive Income 3,254,552 2,699,591 Sales and Marketing Employee Expenditure - Staff wages and superannuation 317,331 261,226 - Other employment expenses 28,780 10,955 346,111 272,181 Other business development related expenditure 125,208 161,123 Per consolidated Statement of Comprehensive Income 471,319 433,303 6 INCOME TAX (a) A reconciliation of income tax expense applicable to accounting loss, before income tax at the statutory income tax rate, to income tax expense at the Group’s effective income tax rate for the periods ended 30 June 2025 and 30 June 2024 is as follows: For the year ended 30 June 2025 $ For the year ended 30 June 2024 $ Accounting loss before tax (6,932,280) (6,554,350) At statutory income tax rate of 25% (2024: 25%) (1,733,070) (1,638,588) Amortisation of intangible assets 244,999 243,975 Deferred tax asset not brought to account 1,488,071 1,394,613 Income tax credit reported in the Statement of Comprehensive Income – – Notes to the Financial Statements continued for the year ended 30 June 2025 44 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3